Literature DB >> 8521412

Genomic alterations and instabilities in renal cell carcinomas and their relationship to tumor pathology.

C A Thrash-Bingham1, H Salazar, J J Freed, R E Greenberg, K D Tartof.   

Abstract

A comprehensive genome scan for loss of heterozygosity (LOH) in 33 renal cell carcinomas indicates that mutations of tumor suppressor genes on several different chromosomes are required for malignant transformation in this disease. In the case of nonpapillary renal carcinomas chromosomes 3p, 6q, 8p, 9pq, and 14q exhibit elevated levels of LOH. Although 3p is the most frequently lost chromosome arm, in no case is 3p observed as the sole allelic loss because it always occurs in conjunction with the loss of either 6q, 8p, or 14q. This result indicates that the mutation of a tumor suppressor gene on 3p, most likely von Hippel-Lindau disease (VHL), may be necessary but is not sufficient for the development of nonpapillary renal cell carcinoma. In papillary renal tumors, LOH is observed most often for chromosomes 6pq, 9p, 11q, 14q, and 21q. This suggests that tumor suppressor genes located on chromosomes 6q, 9pq, and 14q may be involved in the development and/or progression of both nonpapillary and papillary renal cell carcinomas. However, LOH in papillary tumors appears to be especially elevated for 11q and 21q and reduced for 3p and 8p indicating that there are also tumor suppressor genes specific to each form of the disease. There is no correlation between stage of disease and the extent of LOH, loss of a particular chromosome, or the number of chromosomes that show allele imbalance. Early and late stage tumors may exhibit either extensive LOH or no apparent allele loss; similarly, allelic imbalances are observed in both early and late stage renal cell carcinomas. This suggests that a gene (or genes) regulating mitotic chromosome stability may be mutated in some renal tumors. Preliminary evidence points to an association between genome instability and LOH of 14q. Finally, a distinct type of microsatellite instability has been detected in 21% of renal cell carcinomas and occurs at a frequency of 4.4 x 10(-4)/locus. The most common mutation is a 2-bp insertion in a CA repeat. This alteration is not restricted to a particular histopathology or clinical stage, and it is not associated with allelic loss of a specific chromosome. The frequency of this event is similar to that which occurs spontaneously in germline microsatellite loci and is probably not the result of a defect in a mismatch repair gene. It is possible that this type of microsatellite instability is general and may occur in most, if not all, carcinomas.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8521412

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

1.  Physical localisation of the breakpoints of a constitutional translocation t(5;6)(q21;q21) in a child with bilateral Wilms' tumour.

Authors:  P R Hoban; R L Cowen; E L Mitchell; D G Evans; M Kelly; P J Howard; J Heighway
Journal:  J Med Genet       Date:  1997-04       Impact factor: 6.318

2.  NF-κB inhibition by bortezomib permits IFN-γ-activated RIP1 kinase-dependent necrosis in renal cell carcinoma.

Authors:  Roshan J Thapa; Peirong Chen; Mitchell Cheung; Shoko Nogusa; Jianming Pei; Suraj Peri; Joseph R Testa; Siddharth Balachandran
Journal:  Mol Cancer Ther       Date:  2013-05-08       Impact factor: 6.261

3.  Histopathologic subtype-specific genomic profiles of renal cell carcinomas identified by high-resolution whole-genome single nucleotide polymorphism array analysis.

Authors:  Akira Yokomizo; Ken Yamamoto; Kenji Furuno; Masaki Shiota; Katsunori Tatsugami; Kentaro Kuroiwa; Seiji Naito
Journal:  Oncol Lett       Date:  2010-09-23       Impact factor: 2.967

4.  Orthotopic xenografts of RCC retain histological, immunophenotypic and genetic features of tumours in patients.

Authors:  Chiara Grisanzio; Apryle Seeley; Michelle Chang; Michael Collins; Arianna Di Napoli; Su-Chun Cheng; Andrew Percy; Rameen Beroukhim; Sabina Signoretti
Journal:  J Pathol       Date:  2011-06-27       Impact factor: 7.996

5.  CDKNA2A mutation analysis, protein expression, and deletion mapping of chromosome 9p in conventional clear-cell renal carcinomas: evidence for a second tumor suppressor gene proximal to CDKN2A.

Authors:  P Schraml; K Struckmann; R Bednar; W Fu; T Gasser; K Wilber; J Kononen; G Sauter; M J Mihatsch; H Moch
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

6.  Association of glutathione S-transferase M1, T1, and P1 polymorphisms with renal cell carcinoma: evidence from 11 studies.

Authors:  Cheng-You Jia; Yu-Jin Liu; Xian-Ling Cong; Yu-Shui Ma; Ran Sun; Da Fu; Zhong-Wei Lv
Journal:  Tumour Biol       Date:  2013-12-15

7.  The human G2 checkpoint control protein hRAD9 is a nuclear phosphoprotein that forms complexes with hRAD1 and hHUS1.

Authors:  R P St Onge; C M Udell; R Casselman; S Davey
Journal:  Mol Biol Cell       Date:  1999-06       Impact factor: 4.138

8.  Loss of heterozygosity and copy number abnormality in clear cell renal cell carcinoma discovered by high-density affymetrix 10K single nucleotide polymorphism mapping array.

Authors:  Marieta I Toma; Marianne Grosser; Alexander Herr; Daniela E Aust; Axel Meye; Christian Hoefling; Susanne Fuessel; Daniela Wuttig; Manfred P Wirth; Gustavo B Baretton
Journal:  Neoplasia       Date:  2008-07       Impact factor: 5.715

Review 9.  Origin of renal cell carcinomas.

Authors:  Manuel Valladares Ayerbes; Guadalupe Aparicio Gallego; Silvia Díaz Prado; Paula Jiménez Fonseca; Rosario García Campelo; Luis Miguel Antón Aparicio
Journal:  Clin Transl Oncol       Date:  2008-11       Impact factor: 3.405

10.  Evaluation of loss of heterozygosity and microsatellite instability in human pterygium: clinical correlations.

Authors:  E T Detorakis; G Sourvinos; J Tsamparlakis; D A Spandidos
Journal:  Br J Ophthalmol       Date:  1998-11       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.